Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial

Figures & data

Table I. Baseline characteristics of the patients.

Characteristic	Unfractionated heparin (n = 50)	Tinzaparin (n = 46)	P value
Age, years	68 ± 1.7	70 ± 2.0	0.34
Male sex, n (%)	32 (64)	25 (54)	0.34
Hypertension, n (%)	17 (34)	9 (20)	0.11
Diabetes mellitus, n (%)	2 (4)	1 (2)	0.53
Previous ischemic stroke, n (%)	0 (0)	2 (4)	0.23
CHADS2 score			0.50
0, n (%)	18 (36)	15 (33)
1, n (%)	12 (24)	16 (35)
2, n (%)	20 (40)	15 (33)
Ventricular rate, beat/min	138 ± 2.4	139 ± 2.2	0.77
Left atrial dimension, cm	4.3 ± 0.1	4.3 ± 0.1	0.88
Left ventricular ejection fraction, (%)	60 ± 2	67 ± 2	0.03^a
Ventricular rate control agents			0.21
Amiodarone, n (%)	17 (34)	15 (33)
Diltiazem, n (%)	14 (28)	20 (43)
Digoxin, n (%)	19 (38)	11 (24)

^ap < 0.05

CHADS2 score: C, congestive heart failure, H, hypertension; A, age >75 years; D, diabetes mellitus; S2, previous ischemic stroke.

Table II. Characteristics of patients with ischemic stroke/transient ischemic attack.

Sex/age	DM	HT	CHADS2	Ischemic stroke/TIA	aPTT at 6 h	aPTT at 12 h	aPTT at 18 h	aPTT at 24 h
M/69	+	+	2	Ischemic stroke, left parietal infarct	46.1	41.2	41.2	42.7
M/75	−	−	1	Ischemic stroke, cerebellar infarct	38.0	33.8	38.9	40.3
M/78	−	−	1	TIA, left hemiparesis	32.2	25.4	29.4	25.4
F/74	−	−	0	TIA, left hemiparesis	41.4	33.6	33.8	31.6
F/73	−	−	0	TIA, right hemiparesis	28.7	31.8	31.0	40.3

^aPTT, activated partial thromboplastin time; CHADS2 score: C, congestive heart failure; H. hypertension; A, age > 75 years; S2, previous ischemic stroke; DM, diabetes mellitus; HT, hypertension; TIA, transient ischemic attack.